Level of Evidence for Therapeutic Drug Monitoring of Ceftriaxone

被引:4
作者
Dailly, Eric [1 ,2 ]
Verdier, Marie-Clemence [3 ]
Deslandes, Guillaume [1 ]
Bouquie, Regis [1 ,2 ]
Tribut, Olivier [3 ]
Bentue-Ferrer, Daniele [3 ]
机构
[1] CHU Nantes, Serv Pharmacol Clin, F-44035 Nantes 01, France
[2] Univ Nantes, Fac Med Pharm, EA Biostat Pharmacoepidemiol & Mesures Subject Sa, Nantes, France
[3] CHU Pontchaillou, Lab Pharmacol Biol, Rennes, France
来源
THERAPIE | 2012年 / 67卷 / 02期
关键词
therapeutic drug monitoring; ceftriaxone; BROAD-SPECTRUM CEPHALOSPORINS; BETA-LACTAM ANTIBIOTICS; PHARMACODYNAMIC CONSIDERATIONS; STREPTOCOCCUS-PNEUMONIAE; BILIARY PSEUDOLITHIASIS; LIVER INSUFFICIENCY; ACQUIRED PNEUMONIA; PROTEIN-BINDING; RENAL-FAILURE; PHARMACOKINETICS;
D O I
10.2515/therapie/2012018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Level of Evidence for Therapeutic Drug Monitoring of Ceftriaxone. Ceftriaxone is a third generation cephalosporin with an original pharmacokinetics based on a long elimination half-life among cephalosporins, a high protein binding and a dual renal and biliary elimination. Also the pharmacokinetic parameters of ceftriaxone are highly variable in clinical situations such as severe renal insufficiency, liver and renal insufficiency, the elderly, the neonates less than 1 week of age and critically ill patients. In these clinical situations associated or not with high minimal inhibitory concentration (MIC) level, the relationship concentration-clinical outcome based on the ratio between trough plasma concentration and MIC can allow a dose adjustment. Consequently, therapeutic drug monitoring (TDM) of ceftriaxone could be possibly useful in these situations, whereas the necessity of TDM has still to be demonstrated to monitor toxicity.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 41 条
[1]  
[Anonymous], 2009, REV NEUROL PARIS, V165, pF205
[2]  
[Anonymous], RESUME CARACTERISTIQ
[3]   Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children [J].
Avci, Z ;
Koktener, A ;
Uras, N ;
Catal, F ;
Karadag, A ;
Tekin, O ;
Degirmencioglu, H ;
Baskin, E .
ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (11) :1069-1072
[4]   Evaluation of antimicrobial treatments in children with acute otitis media in Spain:: A pharmacokinetic-pharmacodynamic (PK/PD) approach [J].
Beobide, I ;
Canut, A ;
Gascón, AR ;
Isla, A ;
García-Rey, C ;
De La Maza, I ;
Labora, A ;
Pedraz, JL .
JOURNAL OF CHEMOTHERAPY, 2005, 17 (06) :628-635
[5]   PHARMACOKINETICS OF CEFTRIAXONE [J].
BLUMER, J .
HOSPITAL PRACTICE, 1991, 26 :7-13
[6]  
Blumer J, 1991, HOSP PRACT S5, V26, P52
[7]   COMPARATIVE PHARMACOKINETICS OF CEFTRIAXONE AFTER SUBCUTANEOUS AND INTRAVENOUS ADMINISTRATION [J].
BORNER, K ;
LODE, H ;
HAMPEL, B ;
PFEUFFER, M ;
KOEPPE, P .
CHEMOTHERAPY, 1985, 31 (04) :237-245
[8]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[9]   Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis [J].
de Moor, RA ;
Egberts, ACG ;
Schröder, CH .
EUROPEAN JOURNAL OF PEDIATRICS, 1999, 158 (12) :975-977
[10]  
Drugeon HB, 1997, PRESSE MED, V26, P78